Kisspeptin Dosage Chart: 125mcg Daily Before Bed

Kisspeptin is a neuropeptide that acts as the master upstream regulator of the reproductive hormone axis, triggering GnRH release which drives LH and FSH secretion. No kisspeptin formulation is FDA-approved. This is not medical advice.

Research-context information only. Kisspeptin is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Documented Community Protocol

Parameters below reflect community-documented protocols and published clinical dosing ranges — not a recommended schedule.

Cycling Details

The standard protocol is 30 days on / 30 days off. This prevents KISS1R receptor desensitization — continuous kisspeptin exposure causes the receptor to downregulate within hours, blunting LH/FSH output (Dhillo et al., 2005).

Discrete daily injections (rather than continuous infusion) mimic natural pulsatility, since kisspeptin neurons fire in synchronized bursts roughly every 60-90 minutes. The short half-life of kisspeptin-10 (~4 minutes) means the receptor "resets" between daily doses.

Enhanced Protocol (Community)

For kisspeptin-10 users seeking more aggressive stimulation:

Kisspeptin-54 has a longer action window (~4-6 hours of LH elevation), so once daily dosing is typically sufficient. Weight-based clinical dosing: 3.2 nmol/kg SC (~21 mcg/kg for a 70 kg person = ~1,470 mcg).

Routes of Administration

Subcutaneous (standard): Lower abdomen or upper outer thigh. Protocols describe rotating injection sites to prevent lipodystrophy. Trial protocols use 29-31 gauge insulin syringes. No food timing requirements are noted in documented protocols, as subcutaneous injection bypasses GI absorption.

IV (research only): Used in clinical studies for acute LH pulse characterization. Not practical for community use.

Reconstitution Quick Reference

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. 125 mcg ÷ 2,500 = 0.05 mL = 5 units. Community protocols describe swirling gently, refrigerating, and using within 28 days.

For step-by-step reconstitution instructions, see the BPC-157 reconstitution guide — same technique applies to all lyophilized peptides.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Clinical studies where continuous kisspeptin-54 infusion initially spiked LH but then suppressed it after 6-12 hours established the critical importance of pulsatile dosing (Dhillo et al., 2005).

In IVF protocols, kisspeptin-54 has been studied as an alternative oocyte maturation trigger to hCG. A single subcutaneous dose of 12.8 nmol/kg triggered maturation with zero OHSS cases (Abbara et al., 2015; Jayasena et al., 2014).

The 2017 fMRI study found no adverse effects from kisspeptin-54 infusion in healthy men (Comninos et al., 2017), and the 2023 HSDD trial found kisspeptin well-tolerated with no treatment-related serious adverse events (Ertl et al., 2023).

Stacking Protocols

Kisspeptin occupies a unique position as an upstream hormonal regulator. It works through GnRH/LH pathways (hormonal) while PT-141 activates MC4R directly (central arousal) — complementary but unstudied together. For a detailed comparison, see our kisspeptin vs PT-141 comparison.

Side Effects & Safety

• Flushing/warmth — brief, reported in some subjects
• Injection site reactions — mild redness or swelling
• Headache — occasional, mild
• Nausea — rare and mild compared to PT-141 or Melanotan 2
• No bone density loss, hot flashes, or cardiovascular events were reported in the 2023 HSDD trial (Ertl et al., 2023, PMID 36735255)
• Contraindicated in hormone-sensitive cancers (stimulates LH/FSH/sex steroids)
• Pregnancy — insufficient safety data; avoid
• PCOS caution — could worsen LH:FSH ratio imbalance

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once kisspeptin is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 5 mg vial + 5 mL BAC water (1 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

The same math, interactive — pick a vial size and dose to see the exact units to draw and how many doses a vial yields: